Global Hospital Acquired Infections Diagnostics Market Size Study, by Test (Molecular, Conventional), by Infection (UTI, Pneumonia), by Product (Consumables, Instruments), by Type (Blood Tests, Urinalysis), and Regional Forecasts 2022-2032

The global hospital-acquired infections (HAI) diagnostics market was valued at approximately USD 4.23 billion in 2023 and is anticipated to expand at a CAGR of 1.49% over the forecast period 2024-2032. The alarming rise in the prevalence of HAIs, including surgical site infections, bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections, has propelled the demand for rapid and accurate diagnostic solutions. Hospitals, diagnostic laboratories, and healthcare facilities worldwide are increasingly adopting advanced molecular testing methods to curb infection outbreaks and improve patient safety.

The demand for early detection and effective containment of HAIs has intensified, given their impact on hospital mortality rates, prolonged hospital stays, and rising treatment costs. According to the World Health Organization (WHO), nearly 1 in 10 hospitalized patients worldwide is likely to contract an HAI, while the Centers for Disease Control and Prevention (CDC) states that 1 in 31 hospitalized patients in the U.S. acquires an HAI daily. The economic burden associated with HAIs, exceeding USD 28 billion annually in the U.S. alone, further underscores the need for advanced diagnostic tools. The growing threat of multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile (C. difficile), is driving the adoption of molecular diagnostics such as Polymerase Chain Reaction (PCR)-based tests, enabling early detection and effective treatment strategies.

The conventional diagnostic methods segment held a dominant share of the market in 2023, owing to their established reliability and affordability. However, molecular diagnostics, with its ability to offer rapid pathogen detection, is expected to witness the fastest CAGR of 1.71% during the forecast period. Technological advancements such as real-time PCR, multiplex PCR, and next-generation sequencing (NGS) have significantly enhanced diagnostic accuracy and turnaround times, aiding infection control measures in hospitals and intensive care units (ICUs). For instance, in April 2023, Llusern Scientific introduced the Lodestar DX analyzer for rapid urinary tract infection (UTI) diagnostics, emphasizing the growing shift toward advanced molecular detection techniques.

Geographically, Europe dominated the global market in 2023, capturing the largest share due to stringent hospital infection control policies, extensive healthcare expenditure, and the presence of leading diagnostic manufacturers such as bioMérieux and QIAGEN. The Asia-Pacific region is projected to exhibit the fastest growth rate, driven by increasing awareness, rising healthcare investments, and an expanding geriatric population more susceptible to HAIs. Countries like China and India are implementing government-led infection monitoring programs to strengthen HIV, tuberculosis, and antibiotic resistance control measures, further driving market growth. Meanwhile, North America remains a strong contender, given its high prevalence of HAIs, well-established healthcare infrastructure, and ongoing R&D efforts in automated molecular diagnostic systems.

Major market players included in this report are:
• Abbott
• bioMérieux S.A.
• Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company (BD)
• QIAGEN
• Thermo Fisher Scientific Inc.
• Meridian Bioscience, Inc.
• Hologic, Inc.
• Cepheid (Danaher Corporation)
• Bio-Rad Laboratories, Inc.
• Luminex Corporation
• GenePOC Inc.
• T2 Biosystems, Inc.
• Accelerate Diagnostics, Inc.

The detailed segments and sub-segments of the market are explained below:

By Test:
• Molecular
• Conventional

By Infection:
• Urinary Tract Infection (UTI)
• Pneumonia
• Surgical Site Infections
• Bloodstream Infections
• Others

By Product:
• Consumables
• Instruments

By Type:
• Blood Tests
• Urinalysis

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific
• Japan
• China
• India
• Australia
• Thailand
• South Korea

Latin America
• Brazil
• Argentina

Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Years considered for the study are as follows:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032

Key Takeaways:
• Market estimates & forecasts from 2022 to 2032.
• Detailed regional and segmental analysis.
• Competitive landscape with insights into key players and strategic developments.
• Investment opportunities, technological advancements, and regulatory frameworks shaping the industry.
• Analysis of market demand-supply dynamics and consumer behavior trends.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.